Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
182,917,028
-
Total 13F shares
-
95,071,148
-
Share change
-
+2,395,403
-
Total reported value
-
$474,405,111
-
Put/Call ratio
-
173%
-
Price per share
-
$4.99
-
Number of holders
-
143
-
Value change
-
+$9,854,270
-
Number of buys
-
80
-
Number of sells
-
66
Institutional Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q2 2024
As of 30 Jun 2024,
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) was held by
143 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
95,071,148 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., MAVERICK CAPITAL LTD, BlackRock Inc., M28 Capital Management LP, ADAGE CAPITAL PARTNERS GP, L.L.C., 683 Capital Management, LLC, Artal Group S.A., Bellevue Group AG, Kynam Capital Management, LP, and PRIMECAP MANAGEMENT CO/CA/.
This page lists
143
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.